Ind-Swift Laboratories Limited
Registered Office
SCO 850, Shivalik Enclave,
NAC Manimajra, Sector 13,
Chandigarh – 160101 INDIA
info@indswiftlabs.com
0172-2730503, 2730920, 5061851-53
CIN No. L24232CH1995PLC015553

Ref: ISLL:CH:2026 **Date: 4th November, 2026**

The President
Corporate Relationship Department
BSE Limited
Phiroze Jeejeebhoy Towers,
25th Floor, Dalal Street,
Mumbai 400 001

The Vice President,
Listing Compliance Department,
National Stock Exchange of India Limited,
Exchange Plaza, 5th Floor
Plot No. C/2, G-Block,
Bandra Kurla Complex, Bandra (E),
Mumbai 400 051

BSE Scrip Code: 532305

NSE Symbol: INDSWFTLAB

SUBJECT: INVESTOR PRESENTATION ON UN-AUDITED FINANCIAL RESULTS FOR THE QUARTER ENDED SEPTEMBER 30, 2026.

Dear Sir / Ma'am,

Pursuant to Regulation 30 and other applicable provisions, if any, of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, please find attached herewith detailed Investors Presentation on Un-audited Financial Results for the quarter ended September 30, 2026.

Kindly take the above information on record.

Thanking you,
For **IND-SWIFT LABORATORIES LTD.**

PARDEEP VERMA
Digitally signed by PARDEEP VERMA
Date: 2026.11.04 11:23:12 +05'30'

Ind-Swift Laboratories Ltd. CHANDIGARH


PARDEEP VERMA
VP-CORPORATE AFFAIRS &
COMPANY SECRETARY

Ind-Swift Laboratories Limited

One World One Health One Ind-Swift

Ind - Swift Laboratories Limited

Leading Finished Dosage Formulation Manufacturer



INVESTOR PRESENTATION

Q2 & H1 FY27 | Results for the period ended 30 September 2026

MANAGEMENT COMMENTARY

"**Q2FY27** is a **strong validation** of the strategic choices we made earlier. Our transition from an **API manufacturer to a focused FDF manufacturer**, and the **scale-up of operations** on that platform, is now clearly visible in our performance. **Operating income grew over 50%** year-on-year, with **operating EBITDA margin expanding to 18.02%** and **PAT margin to 13.21%**, reflecting the strength of our business model.

The scale-up of our operations is delivering **operating leverage**, while the shift in business mix is **lifting margins**. Raw material cost has come down as a share of revenue, and our growth is coming from core operations rather than other income. Sequentially, revenue and operating EBITDA both grew by **over 25%**, building on a strong Q1. This momentum carried through the first half, with H1FY27 **operating revenue of ₹420.97 crore, up 35.79%**, while operating EBITDA grew more than **4x**.

With a net-debt-free balance sheet, substantial cash and investments, and our **₹250 crore capex programme** funded through **internal accruals**, we are well placed to scale. Supported by **deeper own-brand penetration** in key export markets and the ongoing **Samba EU-GMP upgrade**, we continue to expect FY27 revenue growth of **more than 50%**, a medium-term revenue **CAGR of 20-25%** and EBITDA margin **expansion of 200-300 BPS**. We remain focused on building a **compliance-led, differentiated FDF platform** and **sustaining profitable growth**."



N.R. Munjal
Chairman and Whole Time Director

EVOLUTION & TRANSFORMATION JOURNEY

Ind-Swift Group | Strategic Evolution

1997 — Inception of Ind-Swift Laboratories Ltd.

1998 — Setup of API Manufacturing Facility

2004 — US Subsidiary Incorporated

2005 — 2nd plant commissioned in Jammu

2007 — USFDA Approval

2011 — PMD / USFDA Approval

2012-23 — ANVISA Approval FDA Inspection

2024 — Divested API Unit

2025 — Group Consolidation through merger of Ind Swift Ltd

Ind-Swift Laboratories Ltd. | Growth & Regulatory Milestones

2006 — GBU Manufacturing Plant Established

2007-11 — MHRA Health Canada, ANVISA, Commissioning of Formulation Facility at Jammu

2012 — Day-1 Launch of Generic, Atorvastatin

2013-18 — Philipines, Thailand, South Africa & FDA Approval. Launched patented Ivabradine Oxalate in Europe

2019-22 — Dry Suspension & Shiftpack facility added & Health Canada approval

IND-SWIFT LABORATORIES LTD – “The Before State”

- Incorporated in 1995 as part of the Ind-Swift Group.
- Built as the Group’s dedicated API & CRAMS entity.
- Among India’s largest standalone API manufacturers
- Leadership in macrolides & complex chemistry
- Regulatory approvals from USFDA, MHRA, PMDA, ANVISA, TGA, SFDA, ROF, NCPHP, Health Canada, MoH Oman, CDSCO India, HLfGP-Germany, FDA India
- Proven CRAMS capability with innovator collaborations

APIs across **30+**

Team Size **2500+**

DMFs Filed across 33 molecules **481+**

Therapeutic categories **18**

Largest drug manufacturer in North India

26 Manufacturing Blocks

70+ Countries supplied across regulated + pharmerging markets



Core Business Capabilities

- Complex chemistry API development & scale-up
- Integrated CRAMS operations for innovator projects
- Backward-integrated, cost-efficient manufacturing
- Strong regulatory compliance track record

TRANSACTION SUMMARY & FINANCIAL RESET

Ind-Swift Laboratories Limited
One World One Health One Ind-Swift

Synthimed Labs

Slump Sale :
API & CRAMS business sold to Synthimed Labs Pvt. Ltd.

- Portfolio company of India Resurgence Fund (Bain Capital & Piramal)
- 3 manufacturing sites with USFDA, PMDA, EDQM approvals
- Currently valued at ₹8,000-9,000 Cr (USD 1 bn)

Transaction Summary

Transaction Value :

₹1,650 Cr

Retained Stake

ISLL holds 7.80% equity in Synthimed, continuing the stake in growing APIs.

Strategic Rationale

- Debt Elimination: Proceeds used to repay entire external debt
- Balance Sheet Reset: Transition from a leveraged profile to net debt-free
- Capital Reallocation: Resources freed to invest in higher-margin formulation businesses
- Business Realignment: Strategic exit from capital-intensive API operations
- Value Creation: Framework created for sustainable growth.

POST-TRANSFORMATION OVERVIEW

Post-Transformation Overview

- Strategic exit from API & CRAMS through a ₹1,650 Cr slump sale, making ISLL net debt-free.
- Ind-Swift Limited merged into Ind-Swift Laboratories Limited (Effective 31 March 2024, NCLT-approved).
- Consolidation created a single, streamlined, formulation-focused listed entity.
- Repositioned as a pure-play Finished Dosage Formulation (FDF) company.
- Net debt-free balance sheet enabling growth investments
- Facilities accredited by UK-MHRA, TGA, Health Canada, WHO-GMP, ROF Germany, SFDA-Saudi Arabia, NCPHP-Hungary, MOH-Oman etc.

Key Metrics

900+
Product registrations globally

540+
Product registration owned by Ind-Swift

38+
Years of Experience

2,100+
Dossiers filed

1200+
Team Size

85+
Countries Presence

Post-Merger Business Structure (New Operating Model)

International Division (GBU)

- Presence across 85+ countries.
- Strong CMO relationships & regulated market penetration.
- Extensive dossier pipeline supporting long-term growth.

Domestic Division

- Ethical, Generics, P2P & others (Q-DEN / Nova.)
- 260+ marketing teams covering 20,000 retailers & 25,000+ doctors.
- Network of 3,000 stockists and 14 C&F.

MANUFACTURING INFRASTRUCTURE

Domestic Unit

Samba, J&K



- **Focus**: Domestic formulations (Ethical, Generics, P2P, & others.)
- **Scale:** Spans 14,700 sq. meters.
- **Accreditations:** WHO-GMP, ISO 9001:2008



Acquired **18,000 sq. yds.** of land in **Derabassi** earmarked for dedicated **warehouse development.**

Global Business Unit (GBU)

Derabassi, Punjab



- **Strategic Status:** 100% Export-Oriented Unit (EOU) - Primary revenue engine.
- **Scale:** Spans ≈81,325 sq. meters.
- **Capabilities:** Dedicated blocks for Oral Solid Dosages (Tablets, Capsules, Sachets).
- **Key Approvals:** UK-MHRA, TGA, Health Canada, WHO-GMP, MoH
- **Capacity:** High-volume output capable of supporting >₹10 Billion+ Revenue reach.
- **Tablets:** 9 Billion (9,000 Million) / Annum.
- **Capsules:** 120 Million / Annum.
- **Sachets:** 150 Million / Annum.
- **Sticks:** 184 Million / Annum.
- **Dry Powder in Bottles:** 33 Million / Annum
- **Pellets:** 30 Ton / Annum

R&D CAPABILITES

Infrastructure & Capabilities

- Dedicated Formulation R&D Centre in Panchkula, approved by DST (Govt. of India).
- **70+** specialized scientists focused on Finished Dosage development.
- Strong analytical capabilities: stability studies (ICH), data profiling & analytical method validation.



Core Strengths & Competencies

- **Regulatory Compliance**: Capability for CTD / eCTD dossier preparation targeting UK, EU, Australia, and Canada.
- **Tech Transfer**: Integrated QMS framework ensuring seamless site-transfer from R&D to commercial scale at Derabassi (Export) & Samba (Domestic) units.

Key R&D Metrics (Post-Transformation)

- **Global Filings**: 2100+ dossiers filed across 85+ countries.
- **Success Rate**: 540+ Product registration owned by Ind-Swift.
- **Pipeline**: Active formulation pipeline targeting high-growth therapeutic areas including Cardiac, Anti-diabetic, Urology, Gastrointestinal, CNS, etc

Strategic Achievements

- **Pharmacokinetic Profiling**: Built analytical capability to profile advanced drug delivery systems, such as Gastro-Resistant (GR), Delayed-Release (DR), Multi-Unit Pellet Systems (MUPS), and Prolonged-Release (PR) formulations ensuring superior pharmacokinetic performance.
- **Direct Pivotal BE Profiling:** Leveraged advanced analytical and formulation profiling to advance 6 products directly into pivotal bioequivalence (BE) studies, bypassing the pilot testing stage entirely.





R&D MOLECULE LAUNCH PIPELINE FY27 TO FY30

Ind-Swift Laboratories Limited
One World One Health One Ind-Swift

FY27 TO FY30

A forward-looking portfolio of planned product launches across key therapy areas

2028-29 — 11 MOLECULES

- **Rosuvastatin** — CARDIOVASCULAR
- **Spironolactone** — CARDIOVASCULAR
- **Mirabegron PR** — UROLOGY
- **Rifaximin** — GASTROINTESTINAL
- **Dapagliflozin** — ANTI-DIABETIC
- **Sitagliptin** — ANTI-DIABETIC
- **Linagliptin** — ANTI-DIABETIC
- **Edoxaban** — THROMBOEMBOLIC DISORDER
- **Mesalamine PR** — ULCERATIVE COLITIS
- **Sulfasalazine EC** — ULCERATIVE COLITIS
- **Nitazoxanide** — ANTIPROTOZOAL

2029-30
2 MOLECULES

- **Sacubitril + Valsartan** — CARDIOVASCULAR
- **Empagliflozin** — ANTI-DIABETIC

Potential revenue from these R&D molecules once launched

INTEGRATED BUSINESS LINES

International Engine (Global Business Unit)

Focus: High-Value Exports & Regulated Market

- Dossier-driven model for regulated & semi-regulated markets
- CMO manufacturing for partners in UK, EU, Australia, Canada
- Direct commercial supply in Africa, SEA, Middle East, Mexico, Australia, etc

Contract Manufacturing (CMO):

- Long-term manufacturing contracts (Avg. relationship 9-10+ years).
- High-volume supply to Global Generic Majors.

Greenfield Operations (Own Brands):

- Direct marketing of Ind-Swift branded products.
- 125+ Medical Reps (MRs) deployed in emerging markets (Uzbekistan, East Africa, Myanmar) to capture higher margins.

Out-Licensing (IP-Driven):

- Developing complex generics in-house (R&D) and licensing the Dossier/IP to partners in regulated markets (UK, EU, Australia, Canada).
- Asset: 2,100+ Dossiers filed; 540+ Product registrations owned by Ind-Swift.

Domestic Engine (India Operations)

Comprehensive Market Coverage via multiple Strategic Verticals

Domestic Division serves as the company's "Stability Engine," providing consistent cash flow to balance the high-growth export business.

Ethical Division

- ✓ Branded formulations marketed directly to doctors.
- ✓ High-margin, prescription-driven business.
- ✓ 260+ marketing teams covering 20,000 retailers and 25,000+ doctors.
- ✓ Strong presence in Gynecology & Pediatric therapies
- ✓ Pan-India footprint.

Generic Division

- ✓ Trade generics distributed through 3,000 stockists & 14 C&F network.
- ✓ High-volume, cash-generative segment.

Operates via two verticals:

- HCD (Healthcare Division)
- Agile Division
- Clear growth plan to expand product portfolio and volumes over the next two years.

P2P Division


- ✓ Contract manufacturing for leading Indian pharma companies.
- ✓ (Cipla, Lupin, Mankind, Concord, etc.)
- ✓ 39 active, repeat clients.
- ✓ Jammu facility supports both P2P and ROW (export) supplies.

Others (Q-DEN / NOVA)

- ✓ Customized, multi-specialty manufacturing based on customer requirements
- ✓ Advance-payment model with zero credit risk

DIVERSIFIED MARKETS & CLIENTELE

Ind-Swift Laboratories Limited
One World One Health One Ind-Swift



MANX HEALTHCARE · bluepharma · HEUMANN · TEVA PHARMACEUTICAL INDUSTRIES LTD. · BIOGARAN · KERN PHARMA · VIATRIS · KRKA · EGIS · polpharma · WOCKHARDT · SANDOZ A Novartis Division · STADA · Synthon · AEI Trusted Partner · chanelle · Kent Pharmaceuticals · BB BROWN & BURK · AUROBINDO Committed to Healthier Life · Amarox A subsidiary of

aspen · Ascendis HEALTH · Strides · UNICORN · FORRESTER PHARMA

arrotex PHARMACEUTICALS · api · VIATRIS · generichealth


TERRITORY-WISE EXPORT SALES PERFORMANCE

Q2 FY27 Export mix across Contract Manufacturing and Own Brands



TOTAL EXPORT SALES SHARE:	CONTRACT MANUFACTURING	30.91%	OWN BRANDS	69.09%

GLOBAL MARKET POTENTIAL



- Growing demand for quality branded generics in the GCC region.
- Wholly-owned distribution setup with 100+ Medical Reps and 38 registered products.

- Rapid shift from unbranded to branded generics in a market growing at >10% CAGR.
- Own-brand business built through local distributors; higher gross contribution among export markets.

- Stringent regulatory barriers create a high-margin, low-competition environment.
- Projecting ₹80 Cr in revenue from Macrogol Sachets exports in Australia


- Extensive footprint with 97 Brands registered and presence in key markets like Oman and Qatar.
- The Atorvastatin + Ezetimibe molecule was recently registered in Saudi Arabia, prompting immediate local capex expansion to service new orders.

- High demand for complex generics with limited suppliers.
- The ointment section at the Samba (Jammu) plant is being revamped to EU/PIC/S standards to support Australian and Canadian regulatory approvals.

- Partnership with prominent client in Europe on Atorvastatin + Ezetimibe, expected to generate 100+ Cr from this molecule alone.
- Exclusive worldwide supply agreement with partner, where any required volume of Ibuprofen & Clarithromycin is manufactured solely by Ind-Swift

- World's largest generics market valued at $130 Billion+
- Pivot to Complex Generics & Controlled Substances (ADHD/Niche Molecules).

GLOBAL PRODUCT REGISTRATIONS




PRODUCT REGISTRATIONS EXPECTED IN 2026-27

Ind-Swift Laboratories Limited
One World One Health One Ind-Swift

Number of products registration expected, by region


333
TOTAL PRODUCT REGISTRATIONS EXPECTED IN 2026-27



Products registration expected

- 109 Africa + FWA
- 4 Australia
- 1 Canada
- 21 Central Asia
- 18 Europe
- 19 Latin America
- 17 Middle East
- 144 S.E.A

GLOBAL REGULATORY LANDSCAPE



Emerging Markets
WHO-GMP (Geneva).
MoH UAE.
MoH Russia.
MoH Oman
SFDA Saudi
FDA Taiwan
NCPHP Hungary
PPB Kenya
MoH Afghanistan
SAHPRA
MoH Kingdom of Cambodia
FDA Thailand
NDA Uganda
MoH Nigeria

Regulated Markets
UK-MHRA (United Kingdom).
TGA (Australia).
Health Canada (Canada).
ROF Germany
HLfGP Hessen
CDSCO India

OPERATIONAL & STRATEGIC DEVELOPMENTS – Q2FY27

CDMO/ Own Brands Commercialized: CDMO partnerships/ Own brands with major CDMO partners have been commercialized and are expected to contribute incremental revenue of ₹100-130 Cr in FY27.


New Product Readiness: Commercial validation of Clarithromycin Dry Suspension has been successfully completed, and the product is expected to be commercialized shortly.

Derabassi Warehouse Development: Development work on the Warehouse at the Derabassi unit has commenced under Phase 1 of the capex plan, supporting the company's export-led growth.

Growth in Product Registrations: Global product registrations increased to 900+, compared with 750+ previously, expanding the Company's presence across international markets.


Samba Facility Upgrade: The upgrade of the Samba manufacturing facility to EU-GMP and PIC/S standards is currently underway and progressing as planned. The upgrade is expected to enhance export capabilities, support product filings across regulated markets and strengthen long-term growth visibility.

TOP EXPORT PORTFOLIO MIX



Products (INR Lakhs)	FY25	FY26	Market Size 2024/25 (In USD Billions)	Market Size 2030-35 (In USD Billions)	Source
Atorvastatin	4795.71	8549.74	11.86	19.09	Link
Ezetimibe + Atorvas	2328.13	8077.82	3.5	5.6	Link
Fexofenadine	7967.32	7432.38	1.5	2.1	Link
Metformin	2571.26	2833.61	4,028	6,420	Link
Quetiapine	990.10	1975.22	51.7	65.8	Link
Famciclovir	890.97	1864.06	1.2	2.5	Link
Spagulax	2230.09	1450.49	-	-	-
Aripiprazole	1095.34	755.11	6.68	11.81	Link
Ramipril	2353.62	593.13	1.2	1.8	Link

QUARTERLY SALES BREAKUP SEGMENT WISE



UPCOMING PRODUCT LAUNCH

Products	Market	Projected Revenue (In USD Mn)	Commercialization Year	Market Size 2024/5 (In USD Mn)	Market Size 2030 (In USD Mn)	Source
Ibuprofen Sachet	Europe	12.00	Commercialized	112.7	164.1	Link
Clarithromycin Dry Suspension	Europe	6.00	Commercial Validation Completed	2152.2	3501.43	Link
Macrogol Sachet	UK Australia	5.50	Commercialized	123.0	200.0	Link
Esomeprazole Capsules/ Tablets	Europe Australia	10.00	FY28	1904.4	2872.07	Link
Clarithromycin Dry Suspension	Europe	9.90	FY29	2152.2	3501.43	Link
Ibuprofen Sachet	Europe	0.40	FY29	104.6	205.6	Link

KEY CATALYST & INITIATIVES

Global Demand Surge

- Global pharmaceutical market expected to reach USD 2,350 Billion by 2030. Source
- Strong generic drug demand across regulated + pharmerging geographies.

Export Acceleration

- Scaling Global Business Unit (GBU) with presence in 85+ countries.
- CMO + OWN-Brand exports expected to drive multi-year growth; commercial supplies to one of our partners started in FY27.
- 2,100+ dossiers filed, 540+ registrations owned by Ind-Swift, expanding regulated-market access.`

Cost & R&D Arbitrage

- India's R&D cost base is 87% lower than developed markets.
- 40% of global generics supplied by India. Source

High-Value IP Creation

- 300+ new registrations expected in FY27
- R&D pipeline includes high-barrier molecules (Rosuvastatin, Spironolactone, Mirabegron PR, Rifaxmin, Dapagliflozin, Sitagliptin, Linagliptin, etc).
- Strong R&D infrastructure with focus on differentiated formulations for UK/EU/Australia/Canada.
- Growing out-licensing portfolio across major regulated markets



Domestic Consumption Boom

- Indian pharma market projected to reach from USD 55 Billion USD 130 Billion by 2030, CAGR 12.25%. Source
- Chronic disease prevalence expanding therapy demand (cardiac/diabetic/CNS).

High-Margin Therapy Expansion

- Pivot to Chronic Ethical therapies generating 76% gross margins.
- Leveraging 3,000 stockists and 14 CNFs for nationwide penetration.
- Strategic expansion in Institutional, Nova, and Generics segments.

Regulatory & Policy Push

- Indian Government incentives: PLI Scheme (₹15,000 Cr), tech-upgradation programs, quality-compliance emphasis.
- Rising regulatory scrutiny globally (MHRA/TGA/HC/SFDA), favoring compliant manufacturers.

Global Market Entry Enablement

- Existing approvals (MHRA, TGA, Health Canada, WHO-GMP, SFDA, NCPHP, ROF, MoH Oman, HLfGP) enable multi-market scalability.
- Strengthening QA/QC systems to support CMO scale-up and dossier filings.

GROWTH RATIONALE / FUTURE OUTLOOK

Financial Trajectory

- Topline CAGR **20-25%**, scaling from ₹636 Cr to ₹1,500+ Cr by FY30.
- CDMO to deliver **₹200 to 220 Cr** over 2 years, driven by commercial scale-ups.

Gross Margin uplift from mix-shift toward:

- Domestic Ethical (70-80% GM)
- Export Own Brands (50-55% GM)
- EBITDA margin expansion of **200-300 BPS** led by operating leverage & higher utilization.

Strategic Growth Triggers

- CDMO Partnership Commercialized
- Commercial supplies begin in 2026, **₹100-130 Cr** incremental revenue expected in FY27.

Greenfield Expansion:

- Scaling field-force & distribution in UAE, Uzbekistan, West Africa to move from market entry → market dominance.



Operational & R&D Engine

- **300+ dossier** filings by FY27 to build long-term IP-led revenue visibility.
- Capacity debottlenecking + regulatory capex fully funded through internal accruals.
- Domestic business to grow at **15-20% CAGR**, driven by high-margin Chronic therapies and 3,000 stockists with 14 CNFs.

BOARD OF DIRECTORS



Mr. N.R. Munjal
Chairman and Whole Time Director

- 40+ years of experience expanding the Group’s footprint across 85+ countries with offices in USA, UK, Dubai, & China.
- Drives long-term goals, innovation, and mentors senior leadership for effective business execution.
- Built a high-performance culture of 1,500+ professionals, establishing Ind-Swift as a trusted name in global healthcare.



Mr. Himanshu Jain
Managing Director (Domestic Operations)

- 22+ years of experience specializing in project planning, financial strategy, and operational control.
- Leads the Ethical & Generic verticals, driving expansion and reinforcing the company's impact across domestic and international markets.
- Spearheads the 'Ind-Swift Cares for INDIA' initiative, focusing on healthcare accessibility and organizational development.



Mr. Sahil Munjal
Managing Director (Global Operations)

- 20+ years of experience with deep expertise in IT systems and instrumental development.
- Oversees IT infrastructure and aligns operations with the Global Business Unit (GBU).
- Instrumental in expanding contract manufacturing, out-licensing partnerships, and customer-centric formulation solutions.



Mr. Rishav Mehta
Whole Time Director

- 15+ years of hands-on experience in production management and project planning.
- Oversees manufacturing efficiency, expansion initiatives, and timely execution of critical projects.
- Accelerates new generic product development and process optimization strategies.

EXECUTIVE LEADERSHIP TEAM



Mr. Varun Chabra
President – International Marketing

- 25+ years exp, expanded footprint to 80+ countries.
- Transitioned in 2020 to lead FDF growth, driving own-branding and out-licensing strategies across 5 continents.
- Established subsidiaries in Africa & CIS to strengthen global presence.



Mr. Pardeep Verma
VP Corporate Affairs & CS

- 29+ years exp, Member of ICSI and ICSA (UK).
- Bridges legal compliance with strategic planning, ensures adherence to global governance standards.
- Navigates cross-border regulatory complexities.



Mr. Gagan Agarwal
Chief Financial Officer

- 20+ years exp, rose from Management Trainee to CFO.
- Leads financial architecture, M&A, Investor Relations, and risk governance.
- Ensures financial stability and drives long-term sustainable growth strategies.



Mr. Ravi Bhardwaj
Corporate Quality Head

- 35+ Years of Experience across Quality, formulation R&D & Operations, covering all dosage forms, both sterile and non-sterile.
- Brings 9+ Years of significant international experience with highly regulated global pharmaceutical organizations.
- Associated since 2010 & continues to drive quality excellence and regulatory compliance.



Mr. Vivek Mishra
Vice President Ethical Business

- Leads strategic direction for the Ethical pharmaceutical division.
- Spearheaded the new Delhi marketing office to strengthen market presence.
- Drives value-based marketing and cross-functional teamwork for brand growth.



Mr. Viren Ramakrishna Nagar
Vice President Generic Healthcare

- 40 years exp, MSc, LLB, MBA.
- Leads Generic & Agile divisions, expert in scaling verticals in Tier-2/3 cities.
- Focuses on market-entry strategies and ethical branding to drive double-digit growth



Mr. Anil Agarwal
Chief Operating Officer


- 34+ years of experience leading global pharmaceutical manufacturing across India, Brazil and Japan.
- Extensive past experience in navigating USFDA, MHRA, TGA, and ANVISA audits, remediation of USFDA consent decrees.
- Oversees operations, capacity expansion & regulatory compliance, driving scalable global execution.





Mr. Pratik Kumar
Vice President – R&D

- 28+ years exp, developed 200+ products for US, EU, & Australia.
- Oversees 90+ global patent applications and complex generic development.
- Leads Formulation Dev, Tech Transfer, and Regulatory Affairs.


KEY FINANCIAL METRICS (STANDALONE)









KEY FINANCIAL METRICS (STANDALONE)







Q2 FY27 STANDALONE FINANCIAL HIGHLIGHTS

Particulars (INR Cr)	Q4 FY26	Q1 FY27	Q2FY27	Q-o-Q Change (%)
Revenue	**164.72**	**186.12**	**230.23**	
Operating other income	7.98	-0.03	4.66	
Non operating other income	2.21	7.63	7.60	
Total Revenue	**174.91**	**193.71**	**242.49**	**25.18**
Raw material expense	64.86	75.21	106.04	
Employee benefit expense	37.20	38.95	37.36	
Other expenses	51.94	38.59	49.16	
Total operating EBITDA	**18.69**	**33.32**	**42.33**	**27.04**
Operating EBITDA Margin	**10.82%**	**17.91%**	**18.02%**	**11 BPS**
Total EBITDA including non-operating income	20.90	40.95	49.93	
Finance cost	-2.44	0.71	1.33	
Depreciation	8.08	7.58	7.77	
PBT (Before exceptional items)	**16.87**	**32.66**	**40.82**	
Exceptional Items	5.15	0.24	0.58	
PBT (After exceptional items)	**11.72**	**32.43**	**40.24**	**24.08**
Tax	-3.22	7.98	9.21	
PAT	**14.94**	**24.44**	**31.03**	**26.96**
PAT Margin	**8.65%**	**13.13%**	**13.21%**	**7.70 BPS**

H1 FY27 STANDALONE FINANCIAL HIGHLIGHTS

Particulars (INR Cr)	H1 FY26	H1 FY27	Y-o-Y Change (%)
Revenue	**298.43**	**416.35**	
Operating other income	11.58	4.63	
Non operating other income	20.86	15.23	
Total Revenue	**330.87**	**436.20**	**31.83**
Raw material expense	148.50	181.26	
Employee benefit expense	67.73	76.32	
Other expenses	76.94	87.75	
Total operating EBITDA	**16.98**	**75.65**	**4.5x**
Operating EBITDA Margin	**5.47%**	**17.97%**	**1249.34 BPS**
Total EBITDA including non-operating income	37.84	90.88	
Finance cost	3.17	2.04	
Depreciation	13.65	15.35	
PBT (Before exceptional items)	**20.88**	**73.49**	**3.5x**
Exceptional Items	0.00	0.82	
PBT (After Exceptional items)	**20.88**	**72.67**	
Tax	4.01	17.20	
PAT	**16.88**	**55.47**	**3.3x**
PAT Margin	**5.44%**	**13.18%**	**773.35 BPS**

STANDALONE BALANCE SHEET

Equities & Liabilities (INR Cr)	H1 FY26	H1 FY27
Shareholder's Fund		
Share Capital	81.61	86.96
Reserves & Surplus	1217.04	1373.62
Total Equity	**1298.66**	**1460.59**
Non Current Liabilities		
Long Term Borrowings	8.78	15.14
Long Term Provision	11.78	13.56
Other Non Current Liabilities	6.86	5.96
Total Non Current Liabilities	**27.43**	**34.67**
Current Liabilities		
Short-Term Borrowings	12.77	4.34
Trade Payables	117.09	133.70
Other Current Liabilities	72.29	118.22
Short Term Provision	1.83	2.78
Total Current Liabilities	**203.98**	**259.03**
Total Equity & Liabilities	**1530.06**	**1754.29**

Assets (INR Cr)	H1 FY26	H1 FY27
Non Current Assets		
PP&E	282.84	309.61
CWIP	0.00	41.82
Deferred tax assets	44.63	50.34
Other Non - Current Assets	428.64	434.22
Total Non Current Assets	**756.11**	**835.98**
Current Assets		
Inventories	102.83	168.35
Trade Receivable	168.53	234.79
Cash & Cash Equivalents	388.31	322.81
Investments	19.37	45.03
Other current Assets	94.92	147.32
Total Current Assets	**773.95**	**918.30**
Total Assets	**1530.06**	**1754.29**

STOCK DATA

Ind-Swift Laboratories Limited
One World One Health One Ind-Swift

Stock Performance From 1st Apr 2025 To 30th Oct 2026




As on 02-11-2026

BSE:

Stock Price ₹	367.40
Market Capitalization ₹ Crs	3,194.97
No. of Share Outstanding	8,69,61,558
Face Value ₹	10.00
52 Week High ₹	426.00
52 Week Low ₹	87.00

As on 02-11-2026

Shareholding Pattern



Thank You

Ind Swift Laboratories Ltd.
SCO 850, NAC, Shivalik Enclave,
Manimajra, Chandigarh,
1600101, India
Phone: +91 9814131627
Email: investor@indswiftlabs.com
Website: https://www.indswiftlabs.com/

Investor & Public Relations Consultant

103-8, Lodha Eternis, MIDC,
Andheri East, Mumbai 400093
Maharashtra, India.
Phone: +91 85911 45959
Email: info@confideleap.com
Website: www.confideleap.com

